Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells

Andreas Papapetropoulos, Carolyn Y. Go, Ferid Murad, John D. Catravas

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

1. While exposure of smooth muscle cells to sodium nitroprusside (SNP) leads to the development of tolerance to soluble guanylate cyclase (sGC) activation, the mechanisms responsible for this phenomenon in intact cells remain unclear. In the present study, possible mechanisms of tolerance were investigated in a cell culture model where sGC activity was estimated from the accumulation of cyclic GMP in response to 10 μM SNP over a 15 min period in the presence of a phosphodiesterase (PDE) inhibitor. 2. Pretreatment of rat aortic smooth muscle cells with 10-500 μM SNP led to a dose-dependent downregulation of cyclic GMP accumulation upon subsequent SNP stimulation. This effect was evident as early as 2 h following incubation with 10 μM SNP, reached a plateau at 4 h and was blocked by coincubation with 30 μM oxyhaemoglobin. 3. Pretreatment of smooth muscle cells with the PDE inhibitor, zaprinast, resulted in downregulation of the SNP-induced cyclic GMP accumulation in a time- and concentration-dependent manner, that was first evident after 12 h. Moreover, while the zaprinast-induced downregulation of cyclic GMP accumulation was completely inhibited by the protein kinase A (PKA) inhibitor, H89, tolerance to SNP was partially reversed by H89. 4. β1 sGC steady state mRNA levels of S-nitroso N-acetylpenicillamine (SNAP)- or 8Br-cyclic GMP-pretreated cells were unchanged, as indicated by Northern blot analysis. However, Western blot analysis revealed that a, protein levels were decreased in zaprinast, but not in SNP, SNAP or 8Br-cyclic GMP pretreated cells. 5. While thiol depletion did not prevent the development of tolerance, pretreatment of cells with SNP in the presence of reducing agents partially or completely restored the ability of cells to respond to SNP. 6. We conclude that tolerance to SNP results from two distinct mechanisms: an early onset, NO-mediated event that is reversed by reducing agents and a more delayed, PKA-sensitive process that is mediated through increases in cyclic GMP and a decrease in sGC protein levels.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalBritish Journal of Pharmacology
Volume117
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Nitroprusside
Smooth Muscle Myocytes
Cyclic GMP
S-Nitroso-N-Acetylpenicillamine
Phosphodiesterase Inhibitors
Down-Regulation
Reducing Agents
Cyclic AMP-Dependent Protein Kinases
Oxyhemoglobins
Protein Kinase Inhibitors
Sulfhydryl Compounds
Northern Blotting
Proteins
Cell Culture Techniques
Western Blotting
Messenger RNA

Keywords

  • Cyclic GMP
  • Protein kinase A
  • Sodium nitroprusside
  • Soluble guanylate cyclase
  • Tolerance

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. / Papapetropoulos, Andreas; Go, Carolyn Y.; Murad, Ferid; Catravas, John D.

In: British Journal of Pharmacology, Vol. 117, No. 1, 01.01.1996, p. 147-155.

Research output: Contribution to journalArticle

Papapetropoulos, Andreas ; Go, Carolyn Y. ; Murad, Ferid ; Catravas, John D. / Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. In: British Journal of Pharmacology. 1996 ; Vol. 117, No. 1. pp. 147-155.
@article{d59aa5ab20584c0d9629a1172d1804bb,
title = "Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells",
abstract = "1. While exposure of smooth muscle cells to sodium nitroprusside (SNP) leads to the development of tolerance to soluble guanylate cyclase (sGC) activation, the mechanisms responsible for this phenomenon in intact cells remain unclear. In the present study, possible mechanisms of tolerance were investigated in a cell culture model where sGC activity was estimated from the accumulation of cyclic GMP in response to 10 μM SNP over a 15 min period in the presence of a phosphodiesterase (PDE) inhibitor. 2. Pretreatment of rat aortic smooth muscle cells with 10-500 μM SNP led to a dose-dependent downregulation of cyclic GMP accumulation upon subsequent SNP stimulation. This effect was evident as early as 2 h following incubation with 10 μM SNP, reached a plateau at 4 h and was blocked by coincubation with 30 μM oxyhaemoglobin. 3. Pretreatment of smooth muscle cells with the PDE inhibitor, zaprinast, resulted in downregulation of the SNP-induced cyclic GMP accumulation in a time- and concentration-dependent manner, that was first evident after 12 h. Moreover, while the zaprinast-induced downregulation of cyclic GMP accumulation was completely inhibited by the protein kinase A (PKA) inhibitor, H89, tolerance to SNP was partially reversed by H89. 4. β1 sGC steady state mRNA levels of S-nitroso N-acetylpenicillamine (SNAP)- or 8Br-cyclic GMP-pretreated cells were unchanged, as indicated by Northern blot analysis. However, Western blot analysis revealed that a, protein levels were decreased in zaprinast, but not in SNP, SNAP or 8Br-cyclic GMP pretreated cells. 5. While thiol depletion did not prevent the development of tolerance, pretreatment of cells with SNP in the presence of reducing agents partially or completely restored the ability of cells to respond to SNP. 6. We conclude that tolerance to SNP results from two distinct mechanisms: an early onset, NO-mediated event that is reversed by reducing agents and a more delayed, PKA-sensitive process that is mediated through increases in cyclic GMP and a decrease in sGC protein levels.",
keywords = "Cyclic GMP, Protein kinase A, Sodium nitroprusside, Soluble guanylate cyclase, Tolerance",
author = "Andreas Papapetropoulos and Go, {Carolyn Y.} and Ferid Murad and Catravas, {John D.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1111/j.1476-5381.1996.tb15167.x",
language = "English (US)",
volume = "117",
pages = "147--155",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells

AU - Papapetropoulos, Andreas

AU - Go, Carolyn Y.

AU - Murad, Ferid

AU - Catravas, John D.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - 1. While exposure of smooth muscle cells to sodium nitroprusside (SNP) leads to the development of tolerance to soluble guanylate cyclase (sGC) activation, the mechanisms responsible for this phenomenon in intact cells remain unclear. In the present study, possible mechanisms of tolerance were investigated in a cell culture model where sGC activity was estimated from the accumulation of cyclic GMP in response to 10 μM SNP over a 15 min period in the presence of a phosphodiesterase (PDE) inhibitor. 2. Pretreatment of rat aortic smooth muscle cells with 10-500 μM SNP led to a dose-dependent downregulation of cyclic GMP accumulation upon subsequent SNP stimulation. This effect was evident as early as 2 h following incubation with 10 μM SNP, reached a plateau at 4 h and was blocked by coincubation with 30 μM oxyhaemoglobin. 3. Pretreatment of smooth muscle cells with the PDE inhibitor, zaprinast, resulted in downregulation of the SNP-induced cyclic GMP accumulation in a time- and concentration-dependent manner, that was first evident after 12 h. Moreover, while the zaprinast-induced downregulation of cyclic GMP accumulation was completely inhibited by the protein kinase A (PKA) inhibitor, H89, tolerance to SNP was partially reversed by H89. 4. β1 sGC steady state mRNA levels of S-nitroso N-acetylpenicillamine (SNAP)- or 8Br-cyclic GMP-pretreated cells were unchanged, as indicated by Northern blot analysis. However, Western blot analysis revealed that a, protein levels were decreased in zaprinast, but not in SNP, SNAP or 8Br-cyclic GMP pretreated cells. 5. While thiol depletion did not prevent the development of tolerance, pretreatment of cells with SNP in the presence of reducing agents partially or completely restored the ability of cells to respond to SNP. 6. We conclude that tolerance to SNP results from two distinct mechanisms: an early onset, NO-mediated event that is reversed by reducing agents and a more delayed, PKA-sensitive process that is mediated through increases in cyclic GMP and a decrease in sGC protein levels.

AB - 1. While exposure of smooth muscle cells to sodium nitroprusside (SNP) leads to the development of tolerance to soluble guanylate cyclase (sGC) activation, the mechanisms responsible for this phenomenon in intact cells remain unclear. In the present study, possible mechanisms of tolerance were investigated in a cell culture model where sGC activity was estimated from the accumulation of cyclic GMP in response to 10 μM SNP over a 15 min period in the presence of a phosphodiesterase (PDE) inhibitor. 2. Pretreatment of rat aortic smooth muscle cells with 10-500 μM SNP led to a dose-dependent downregulation of cyclic GMP accumulation upon subsequent SNP stimulation. This effect was evident as early as 2 h following incubation with 10 μM SNP, reached a plateau at 4 h and was blocked by coincubation with 30 μM oxyhaemoglobin. 3. Pretreatment of smooth muscle cells with the PDE inhibitor, zaprinast, resulted in downregulation of the SNP-induced cyclic GMP accumulation in a time- and concentration-dependent manner, that was first evident after 12 h. Moreover, while the zaprinast-induced downregulation of cyclic GMP accumulation was completely inhibited by the protein kinase A (PKA) inhibitor, H89, tolerance to SNP was partially reversed by H89. 4. β1 sGC steady state mRNA levels of S-nitroso N-acetylpenicillamine (SNAP)- or 8Br-cyclic GMP-pretreated cells were unchanged, as indicated by Northern blot analysis. However, Western blot analysis revealed that a, protein levels were decreased in zaprinast, but not in SNP, SNAP or 8Br-cyclic GMP pretreated cells. 5. While thiol depletion did not prevent the development of tolerance, pretreatment of cells with SNP in the presence of reducing agents partially or completely restored the ability of cells to respond to SNP. 6. We conclude that tolerance to SNP results from two distinct mechanisms: an early onset, NO-mediated event that is reversed by reducing agents and a more delayed, PKA-sensitive process that is mediated through increases in cyclic GMP and a decrease in sGC protein levels.

KW - Cyclic GMP

KW - Protein kinase A

KW - Sodium nitroprusside

KW - Soluble guanylate cyclase

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0030052615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030052615&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.1996.tb15167.x

DO - 10.1111/j.1476-5381.1996.tb15167.x

M3 - Article

C2 - 8825356

AN - SCOPUS:0030052615

VL - 117

SP - 147

EP - 155

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -